Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Receivables - Other (2016 - 2021)

Corbus Pharmaceuticals Holdings has reported Receivables - Other over the past 5 years, most recently at $2.5 million for Q3 2021.

  • For Q3 2021, Receivables - Other rose 160.39% year-over-year to $2.5 million; the TTM value through Sep 2021 reached $2.5 million, up 160.39%, while the annual FY2020 figure was $1.6 million, 39.64% down from the prior year.
  • Receivables - Other for Q3 2021 was $2.5 million at Corbus Pharmaceuticals Holdings, up from $2.4 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $4.4 million in Q1 2020 and troughed at $500000.0 in Q3 2017.
  • A 4-year average of $2.2 million and a median of $2.3 million in 2021 define the central range for Receivables - Other.
  • On a YoY basis, Receivables - Other climbed as much as 160.39% in 2021 and fell as far as 49.0% in 2021.
  • Year by year, Receivables - Other stood at $500000.0 in 2017, then surged by 436.21% to $2.7 million in 2019, then tumbled by 39.64% to $1.6 million in 2020, then skyrocketed by 54.48% to $2.5 million in 2021.
  • Business Quant data shows Receivables - Other for CRBP at $2.5 million in Q3 2021, $2.4 million in Q2 2021, and $2.3 million in Q1 2021.